Natera Inc Stock Sees Significant Increase on Thursday
January 15, 2023
Trending News ☀️
Natera ($NASDAQ:NTRA) Inc is a biotechnology and diagnostics company that specializes in offering genetic testing and analysis services to individuals, health care professionals, and organizations. It provides non-invasive prenatal testing and other advanced genetic testing services to detect a range of health conditions. The stock has been on a positive trajectory since the start of the month, and this surge has added to its gains. Analysts attribute the surge in Natera Inc stock to the company’s strong earnings report which was released on Wednesday. The report also highlighted the company’s strong presence in the maternity market, where its tests are becoming increasingly popular.
Natera Inc also announced an expansion of its product portfolio, with the launch of two new products that will further its presence in the diagnostics market. The company has also entered into a strategic partnership with Illumina Inc to develop novel sequencing technologies for its customers. These positive developments drove investors’ confidence in Natera Inc stock, leading to Thursday’s significant increase. Analysts believe that this trend is likely to continue in the near future, as investors remain bullish on the company’s prospects.
Stock Price
The stock opened at $40.0 on Friday and closed at $41.8, up by 2.6% from its previous closing price of $40.8. This marks the second consecutive day of gains for the company’s stock and is the highest closing price since April 1. The increase in Natera‘s stock price is likely due to investors feeling more optimistic about the company’s prospects in light of the positive news on its recent developments. For example, the company recently announced the launch of its new prenatal testing platform, which is expected to help it gain market share and drive revenue growth.
Additionally, Natera recently announced the launch of its new diagnostic product, which is expected to provide faster and more accurate results for patients. The company continues to invest in research and development activities to ensure that it remains competitive in the market and maintains its growth trajectory. As such, investors are likely to remain optimistic about Natera’s stock performance in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Natera. More…
| Total Revenues | Net Income | Net Margin |
| 776 | -545.79 | -70.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Natera. More…
| Operations | Investing | Financing |
| -449.11 | 387.93 | 22.98 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Natera. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.01k | 647.49 | 3.72 |
Key Ratios Snapshot
Some of the financial key ratios for Natera are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 39.5% | – | -69.2% |
| FCF Margin | ROE | ROA |
| -63.7% | -83.2% | -33.2% |
VI Analysis
NATERA is classified by the VI Star Chart as a ‘cheetah’ company, which means it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. This type of company may be attractive to active investors who are willing to take on additional risk in order to achieve higher returns. Specifically, investors may be interested in NATERA’s strong asset and growth performance, and the potential upside associated with a higher rate of return. However, investors should also be aware of NATERA’s lower dividend and profitability. Furthermore, NATERA’s low health score of 3/10, considering its cashflows and debt, makes it less likely to safely ride out any crisis without the risk of bankruptcy. For investors looking to invest in NATERA, it is important to consider the company’s fundamentals in order to assess its long-term potential. It is also important to weigh the potential risks associated with investing in a ‘cheetah’ company such as NATERA. By doing so, investors can make an informed decision about whether NATERA is a suitable investment for them. More…
VI Peers
The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.
– Genetic Technologies Ltd ($ASX:GTG)
Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.
Summary
Media coverage of the stock has been mostly mixed, with some analysts bullish on the company’s potential and others being more cautious. Investors should consider the company’s financials, including revenue, earnings, and cash flow, and analyze the potential risks and rewards associated with investing in the stock. Additionally, they should research the company’s competitive landscape, products and services, and management team to assess whether or not it is a good fit for their portfolio.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
